HeartBeam, a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that its management team will participate in several investor and industry conferences throughout March 2026. CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, which will include a webcast presentation on March 16. The executives will also meet with institutional and retail investors during the event.
The company's leadership will also be present at the 38th Annual ROTH Conference in Dana Point, California, on March 23-24. At this conference, CEO Robert Eno will join a panel discussion focused on technologies that are advancing healthy aging, positioning HeartBeam within the broader context of healthcare innovation for an aging population.
Furthermore, Eno, alongside Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger, will attend ACC.26, the American College of Cardiology's annual scientific conference from March 28-30. This event represents a critical platform for the company to engage directly with the medical community. At ACC.26, HeartBeam plans to showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners.
HeartBeam is developing technology designed to transform the detection and monitoring of critical cardiac conditions. The company is creating what it describes as the first-ever cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions, from three non-coplanar directions, and synthesizing those signals into a standard 12-lead ECG. This platform technology is intended for portable devices that can be used wherever a patient is located, aiming to deliver actionable heart intelligence outside of traditional medical facilities.
The potential impact of this technology is significant for business and technology leaders monitoring the healthcare sector. By enabling physicians to identify cardiac health trends and acute conditions remotely, the technology could redefine cardiac health management, potentially reducing hospital visits and enabling more proactive care. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology enablement.
For investors and industry observers, the company's conference participation provides multiple touchpoints for evaluation. The Oppenheimer and ROTH conferences offer insights into the company's financial strategy and market positioning, while ACC.26 serves as a direct channel to the clinical community that will ultimately adopt the technology. The demonstration of the 12-lead ECG patch prototype is particularly notable, as it represents a tangible step toward commercializing a wearable form factor for comprehensive cardiac monitoring.
The broader implications for the medical technology industry involve the continued convergence of digital health, remote patient monitoring, and cardiology. HeartBeam's approach aligns with growing trends toward decentralized healthcare and data-driven diagnostics. Success in this area could influence standards of care, reimbursement models, and competitive dynamics within the cardiac monitoring device market. The latest news and updates relating to HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.
